Business Context and Reporting Period
This Form 8-K filing by Ironwood Pharmaceuticals, Inc. (IRWD) reports a change in the company's independent registered public accounting firm. The report date is July 3, 2025, with the document signed on July 10, 2025.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on the transition of the external auditor.
Material Changes
- Dismissal of Auditor: On July 3, 2025, the Audit Committee dismissed Ernst & Young LLP (EY) as the independent registered public accounting firm following a competitive proposal review.
- Appointment of Successor: KPMG LLP was appointed as the new independent registered public accounting firm, effective immediately for the fiscal year ending December 31, 2025.
- Audit Opinion History: EY's reports on consolidated financial statements for fiscal years 2023 and 2024 did not contain adverse opinions or disclaimers regarding the financial statements themselves. However, EY issued an adverse opinion on the Company's internal control over financial reporting as of December 31, 2024.
- Material Weaknesses: The adverse opinion on internal controls was due to material weaknesses in entity-level controls, information technology general controls, financial statement close process controls, and expenditures controls. These weaknesses did not result in a restatement of previously issued financial statements.
Guidance, Outlook, and Risks
The filing contains no financial guidance or outlook. The primary risk disclosed relates to the previously identified material weaknesses in internal controls over financial reporting. The Company has authorized EY to respond to inquiries from KPMG regarding these weaknesses. No disagreements or reportable events occurred between the Company and EY regarding accounting principles or audit scope, aside from the noted control deficiencies.
Investor Verification Checklist
- Verify the status of remediation efforts for the material weaknesses in internal controls identified in the 2024 10-K.
- Review the letter from EY (Exhibit 16.1) to confirm their agreement with the Company's statements regarding the dismissal.
- Monitor future filings for the transition timeline and initial audit scope defined by KPMG.
- Confirm that no restatements of prior financial periods are anticipated despite the adverse opinion on internal controls.